{
    "Trade/Device Name(s)": [
        "Yumizen C1200 Creatinine PAP"
    ],
    "Submitter Information": "HORIBA ABX SAS",
    "510(k) Number": "K193649",
    "Predicate Device Reference 510(k) Number(s)": [
        "K110137"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JFY"
    ],
    "Summary Letter Date": "October 7, 2020",
    "Summary Letter Received Date": "October 9, 2020",
    "Submission Date": "October 7, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.1225"
    ],
    "Regulation Name(s)": [
        "Creatinine test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Creatinine"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma",
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Yumizen C1200 Clinical Chemistry Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic colorimetric test",
        "Photometric end-point reaction"
    ],
    "Methodologies": [
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Yumizen C1200 Creatinine PAP enzymatic reagent for quantitative measurement of creatinine in serum, plasma, and urine using Yumizen C1200 analyzer",
    "Indications for Use Summary": "Intended for quantitative in vitro diagnostic determination of creatinine in human serum, plasma, and urine to aid in diagnosis and treatment of renal diseases, monitoring renal dialysis, and as a basis for measuring other urine analytes",
    "fda_folder": "Clinical Chemistry"
}